J Am Vet Med Assoc. 2024 Jul 19;262(11):1-7. doi: 10.2460/javma.24.02.0109. Print 2024 Nov 1.
To determine the clinical significance of performing repeated postchemotherapy CBC for cancer-bearing dogs receiving ≥ 4 carboplatin treatments. The secondary aim was to identify risk factors associated with cumulative carboplatin-induced neutropenia in those dogs.
40 client-owned dogs diagnosed with cancer.
A retrospective study using medical records from a single academic institution during 2012 to 2023. Dogs that received ≥ 4 doses of carboplatin with pre- and postchemotherapy CBCs available were included. Signalment and possible risk factors were recorded. Veterinary Cooperative Oncology Group-Common Terminology Criteria for Adverse Events was used for neutropenia grading.
40 dogs met the inclusion criteria, with a total of 206 prechemotherapy and 188 postchemotherapy CBC results available. The median carboplatin dosage was 300 mg/m2 (range, 200 to 300 mg/m2). The median interval between carboplatin administration and the postchemotherapy CBC was 10 days (range, 6 to 38 days). Eleven dogs developed a grade 2 or higher neutropenia, with 5 dogs developing multiple neutropenic events, for a total of 18 separate events (18/394). Only 2 of 18 neutropenic events were recorded at the 10- to 14-day postchemotherapy CBC. The yield of detecting neutropenia at a postchemotherapy CBC at any carboplatin chemotherapy after the second dose was < 1% (1/149). Dogs that developed neutropenia at the pre-2nd chemotherapy CBC had a significantly higher risk of developing another neutropenic event at subsequent prechemotherapy CBC (P < .001).
The incidence of cumulative neutropenia after 4 to 6 doses of carboplatin is low in cancer-bearing dogs. If a grade 2 or higher neutropenia is observed at or before the second prechemotherapy CBC, the dog is at a higher risk of developing neutropenia following future treatments.
确定对接受≥4 次卡铂治疗的癌症犬进行多次化疗后 CBC 的临床意义。次要目的是确定与这些犬的累积卡铂诱导中性粒细胞减少相关的风险因素。
40 只被诊断患有癌症的患犬。
这是一项使用 2012 年至 2023 年期间单一学术机构的病历进行的回顾性研究。纳入接受了≥4 次卡铂治疗且有化疗前后 CBC 结果的犬。记录了犬的一般信息和可能的风险因素。使用兽医合作肿瘤学组常见不良事件术语标准对中性粒细胞减少症进行分级。
40 只犬符合纳入标准，共获得 206 次化疗前和 188 次化疗后 CBC 结果。卡铂的中位剂量为 300mg/m2（范围，200-300mg/m2）。卡铂给药与化疗后 CBC 之间的中位间隔为 10 天（范围，6-38 天）。11 只犬发生了 2 级或更高等级的中性粒细胞减少症，其中 5 只犬发生了多次中性粒细胞减少事件，共发生了 18 次（18/394）。只有 2 次中性粒细胞减少事件发生在化疗后 10-14 天的 CBC 中。在第二次化疗后的任何一次卡铂化疗后进行化疗后 CBC 检测中性粒细胞减少的检出率<1%（1/149）。在第 2 次化疗前 CBC 中发生中性粒细胞减少的犬，在随后的化疗前 CBC 中发生另一次中性粒细胞减少事件的风险显著增加（P<0.001）。
在接受 4-6 次卡铂治疗的癌症犬中，累积中性粒细胞减少的发生率较低。如果在第 2 次化疗前的 CBC 中观察到 2 级或更高等级的中性粒细胞减少，那么该犬在接受未来治疗后发生中性粒细胞减少的风险更高。
